Anti-Cancer Drugs Get Cheaper: NPPA Caps Trade Margins on 137 Medicines, MRPs of 1,364 Formulations Revised - UPSC Notes

On 9 November 2026, revised maximum retail prices (MRPs) of 1,364 anti-cancer formulations came into effect across India, after the National Pharmaceutical Pricing Authority (NPPA) capped the trade margins on the MRP of 137 anti-cancer drugs. The decision follows the recommendations of an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare, on 17 October 2026 (PIB, Department of Pharmaceuticals).

Key numbers

• 1,364 formulations of 121 anti-cancer drugs have reported revised MRPs, from 85 pharmaceutical companies (as on 8 November 2026).
• 679 brands have reported price reductions of more than 50 per cent.
• The highest reported MRP reduction is 96.45 per cent.
• Estimated annual savings to consumers: Rs 3,540.38 crore.

What a trade margin cap means

Instead of fixing the ceiling price of a medicine directly, NPPA caps the trade margin - the combined mark-up taken by stockists, distributors and retailers - on the MRP. When the margin is capped, the MRP printed on the pack must fall. No chemist or hospital pharmacy may charge more than the revised MRP.

How consumers can check and complain

• Check the revised MRP printed on the medicine pack.
• Verify medicine prices on the Pharma Sahi Daam mobile app or the NPPA website (nppa.gov.in).
• Report overcharging through the Pharma Jan Samadhan portal or the NPPA helpline 1800-111-255.

About NPPA and the DPCO

• NPPA was set up in 1997 under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. It is not a statutory body.
• It fixes and revises ceiling prices of scheduled medicines and enforces the Drugs (Prices Control) Order (DPCO), issued under the Essential Commodities Act, 1955.
• The trade-margin route was first used in 2019, when NPPA capped trade margins for 42 non-scheduled anti-cancer medicines; the present action extends the same approach on a much larger scale.

UPSC angle

• GS-II (Health and Governance): drug price regulation, affordability of cancer care, role of NPPA and DGHS, and grievance redress tools like Pharma Sahi Daam and Pharma Jan Samadhan.
• GS-III (Economy): price controls versus market pricing, trade margin rationalisation, and the pharmaceutical sector in India.
• Prelims pointers: NPPA (1997, under Department of Pharmaceuticals), DPCO under the Essential Commodities Act 1955, National List of Essential Medicines.

Source: PIB release, Department of Pharmaceuticals, 9 November 2026 ("Revised MRPs of 1,364 Anti-Cancer Formulations Come into Effect from Today").